Early Access — free while we kick the tires
EdgarHawk

KEATING MELVIN L

Director

Director
2 filings analyzed · 1 company · Latest 2026-03-18

Companies

Company Buys Sells Direction
AGILYSYS INC AGYS 16 0 Net buying

Activity

March 2026
2026-03-18 AGILYSYS INC AGYS
medium
Buy
400 shares
$27,289
Significance 6/10

Director Melvin Keating buys 400 shares at blended $68.22 avg; stock now down -52.1% from 52-week high.

Melvin Keating, Director, executed 6 separate purchases totaling 400 shares for $27,289.30 across March 16–17, 2026, at prices ranging from $67.98 to $68.49 (blended average $68.22). This modest 1.1% increment to his holdings comes as AGYS has declined -17.1% over the past 30 days and -44.6% over 90 days, trading $67.54 compared to its 52-week high of $141.12. His recent prior purchases at this ticker (Feb 3, 2026) each posted negative 30-day returns (-3.7% to -5.8%), suggesting a pattern of accumulation into a sustained decline. Fundamentally, the company reports $80.4M quarterly revenue, $9.9M net income, 16.1% annual growth, and a 62.54 P/E ratio at a $1.9B market cap—characteristics that may have motivated the director's continued buying, though the recent price trajectory and his prior at-ticker timing record warrant investor attention.

February 2026
2026-02-03 AGILYSYS INC AGYS
high
Buy
600 shares
$50,379
Significance 6/10

Director Keating purchased 600 shares across 10 transactions totaling $50.4K; stock down 27.4% in 30 days, 33.5% in 90 days

KEATING MELVIN L, a Director at AgilySys, executed 10 separate open-market purchases totaling 600 shares for $50,378.90 between January 30 and February 3, 2026, at a blended average price of $83.96, increasing his holdings from 34,407 to 35,007 shares. The timing warrants attention: the stock is currently trading at $83.87, down 27.4% over the past 30 days and 33.5% over 90 days from a 52-week high of $141.12, placing it near the lower end of its 52-week range. Notably, Keating's 5 prior open-market purchases at AgilySys (all between February and March 2024) demonstrated strong 90-day outcomes, with returns ranging from +23.4% to +33.1%, suggesting a consistent pattern of well-timed entries at this ticker; however, the company's current fundamentals show a P/E of 77.66 and recent revenue of $80.4M with net income of $9.9M, meriting scrutiny as the substantial recent price decline may or may not reflect fundamental deterioration versus market sentiment.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access